Neutral Cipla; target of Rs 1450: Motilal Oswal

What happened

Motilal Oswal reported that Cipla's 2QFY27 revenue was largely in line, while EBITDA beat expectations by 5% on higher gross margin and lower research and development spending. Earnings matched expectations because lower other income and a higher tax rate offset the EBITDA beat. Motilal Oswal maintained a Neutral rating with a target of Rs 1450.

Confirmed

Global impact / market context

A Neutral rating with a Rs 1450 target means the analyst sees limited upside from current levels. The profit beat came partly from lower research spending, so investors should consider whether cost savings can repeat or whether they reflect delayed investment.

Analyst inference

Cipla's India business gained from strong chronic therapy offtake, better acute therapy industry growth, consumer health execution and trade generics improvement. The 22x forward earnings valuation, which means price relative to expected profits, leaves little room for error if growth slows.

Analyst inference

What to watch

1. Cipla's India growth relied on chronic therapies, acute therapy industry improvement, consumer health and trade generics, so watch whether these drivers continue in coming quarters. Confirmed
2. Watch whether Cipla increases research and development spending after the lower-than-expected amount this quarter, which could raise costs and reduce future profit growth. Proposed
3. Track whether other income and the tax rate normalize, since these offset the EBITDA beat and could keep earnings flat even if operating profit improves. Analyst inference

Evidence

• Original source link unavailable